Professor Robert Clarke
- BEST-D: Biochemical Efficacy and Safety Trial of Vitamin D
- China Kadoorie Biobank
- HPS: Heart Protection Study
- PROCARDIS Sibling-pair Studies of Genetic Determinants of MI
- Re-survey and Follow-up of 1970 Whitehall Study
- SEARCH: Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine
MD, FRCP, FFPH, FFPHI, MSc, DCH
Professor of Epidemiology and Public Health Medicine
- Clinical Trial Service Unit and Epidemiological Studies Unit
Robert Clarke is a Professor of Epidemiology and Public Health Medicine at the Clinical Trial Service Unit (CTSU), Nuffield Department of Population Health, University of Oxford and Consultant in Public Health Medicine and Director of the MSc course in Global Health Science. He qualified in clinical medicine in Ireland and worked for 5 years in internal medicine and 4 years in cardiology. After 2 years in clinical pharmacology at Vanderbilt University, Nashville, USA, he joined CTSU in 1991 and specialised in Cardiovascular Epidemiology.
His main research interests are to understand the importance of classical and novel risk factors for occlusive vascular diseases. He led several large observational studies and meta-analyses of observational studies and randomized trials (eg, Whitehall study, PROCARDIS, CARDIoGRAMplusC4D, B-Vitamin Treatment Trialists’ Collaboration and the BEST-D trial). He also worked extensively on the Prospective Studies Collaboration and the China Kadoorie Biobank (CKB) study. He currently leads a research programme to assess the importance of blood pressure, blood lipids, and novel biomarkers (including genetic markers, cytokines, proteomics and metabolomics) for occlusive vascular diseases in the CKB study. His work has been widely cited (200 publications, H-index of 54) and is listed in Tomson Reuters’ Most Influential Scientific Minds 2014.
Probability of chronic kidney disease and associated risk factors in Chinese adults: a cross-sectional study of 9 million Chinese adults in the Meinian Onehealth screening survey.
Zhuang Z. et al, (2022), Clin Kidney J, 15, 2228 - 2236
The role of NMR-based circulating metabolic biomarkers in development and risk prediction of new onset type 2 diabetes.
Bragg F. et al, (2022), Sci Rep, 12
Systematic review of the utility of the frailty index and frailty phenotype to predict all-cause mortality in older people.
Kim DJ. et al, (2022), Syst Rev, 11
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.
Cholesterol Treatment Trialists' Collaboration None., (2022), Lancet (London, England), 400, 832 - 845
Risks of Stroke and Heart Disease Following Hysterectomy and Oophorectomy in Chinese Premenopausal Women.
Poorthuis MHF. et al, (2022), Stroke